Author

David Liu 1

1 Peter MacCallum,Surgical Oncology Research Laboratory,Melbourne,Australia

SPECIFIC BMP4 INHIBITION AS A POTENTIAL THERAPEUTIC STRATEGY FOR SMAD4 DEFECTIVE ESOPHAGEAL ADENOCARCINOMAS

Silvia Calpe, Matthew Read, Sanne Hoefnagel, Maria del carmen Sancho Serra, Danielle Straub, Ana Correia, Nick Clemons, David Liu, Wayne Phillips, Kausilia K. Krishnadath

REMODELING BARRETT’S METAPLASIA IN A NOVEL IN VIVO HUMANORGANOID MODEL

Ana Correia, Matthew Read, Silvia Calpe, Nicholas Clemons, David Liu, Cuong Duong, Wayne Phillips, Kausilia K. Krishnadath

PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING ORAL ADMINISTRATION OF PTG-100, A PEPTIDE ANTAGONIST OF INTEGRIN ?4?7

Thamilarasi Annamalai, Larry Mattheakis, ASHOK BHANDARI, David Liu, Genet Zemede, Sarah Hadley, Li Zhao, NAMITHA RAO

SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ORAL PEPTIDE THERAPEUTIC PTG-100 (ALPHA4-BETA7 INTEGRIN ANTAGONIST) IN NORMAL HEALTHY VOLUNTEERS

Richard Shames, Lucio Tozzi, Larry Mattheakis, THAMIL ANNAMALAI, ASHOK BHANDARI, David Liu

Safety, Tolerability, and Pharmacokinetics of PTG-200, An Oral GI-restricted Peptide Antagonist of IL-23 Receptor, In Normal Healthy Volunteers

Lili Xiaoli Cheng, Tien-Yi Lee, Grace Ledet, James Tovera, Robert Campbell, Norbert Purro, THAMIL ANNAMALAI, ASHOK BHANDARI, Mohammad Masjedizadeh, David Liu, Roya Nawabi, Bittoo Kenwar

Item 1 - 5 / 5
1